WASHINGTON, Sept. 10, 2025 — President Donald J. Trump has directed federal health regulators to tighten oversight of prescription drug advertising, citing concerns that current practices mislead consumers and downplay risks.
In a presidential memorandum released Tuesday, Trump instructed the Secretary of Health and Human Services and the Commissioner of Food and Drugs to take immediate steps to enforce stricter standards on direct-to-consumer (DTC) drug advertisements.
“Drug advertising has skyrocketed in recent decades, often encouraging medications over lifestyle changes and privileging costly brand-name drugs over cheaper generics,” the memo stated.
Under the new directive, the Food and Drug Administration (FDA) will be tasked with ensuring that all prescription drug ads provide “fair, balanced, and complete information” — with particular emphasis on clearly presenting risks associated with use.
The memorandum underscores that the goal is to protect American consumers by restoring transparency and accuracy to pharmaceutical advertising, though it clarifies that it does not create new legal rights enforceable in court.
The move comes amid growing public debate over the influence of pharmaceutical advertising, which remains legal in the United States but banned in most other countries.
